Journal article icon

Journal article

Capecitabine: have we got the dose right?

Abstract:

In the past 5-10 years there has been a growing trend for substituting conventional 5-fluorouracil with the oral prodrug of 5-fluorouracil, capecitabine, in chemotherapy regimens. This regimen change is based on evidence of the efficacy equivalence of these two drugs and the lack of an increase in overall toxic effects when capecitabine is used. Many investigators in different parts of the world have determined their own starting dose for capecitabine, usually based on their experience of tox...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1038/ncponc1240

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Journal:
Nature clinical practice. Oncology
Volume:
6
Issue:
1
Pages:
17-24
Publication date:
2009-01-05
DOI:
EISSN:
1743-4262
ISSN:
1743-4254
URN:
uuid:215c4c92-01c2-4ce0-9850-3021e8433d14
Source identifiers:
175134
Local pid:
pubs:175134

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP